Quick Answer
GALECTIN THERAPEUTICS INC reported Cash and Equivalents of $17.72 million for fiscal year 2025.
GALECTIN THERAPEUTICS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $17.72M | +17.2% |
| 2024 | $15.12M | -41.1% |
| 2023 | $25.66M | +38.0% |
| 2022 | $18.59M | -53.1% |
| 2021 | $39.65M | +46.1% |
| 2020 | $27.14M | -42.8% |
| 2019 | $47.48M | +475.3% |
| 2018 | $8.25M | +170.3% |
| 2017 | $3.05M | -80.1% |
| 2016 | $15.36M | -40.6% |
| 2015 | $25.85M | -11.3% |
| 2014 | $29.13M | +177.7% |
| 2013 | $10.49M | +12.0% |
| 2012 | $9.36M | +46.4% |
| 2011 | $6.40M | +8.6% |
| 2010 | $5.89M | +2247.0% |
| 2009 | $251.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.53M | -57.4% | -16.3% |
| June 30, 2025 | $13.77M | -46.2% | +85.3% |
| March 31, 2025 | $7.43M | -68.5% | -50.9% |
| December 31, 2024 | $15.12M | -41.1% | -44.1% |
| September 30, 2024 | $27.06M | +32.9% | +5.7% |
| June 30, 2024 | $25.60M | +42.5% | +8.7% |
| March 31, 2024 | $23.55M | +32.3% | -8.2% |
| December 31, 2023 | $25.66M | +38.0% | +26.0% |
- GALECTIN THERAPEUTICS INC showed an increase of +17.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, GALECTIN THERAPEUTICS INC’s cash and equivalents has grown by 6959.8% (from $251.0 thousand to $17.72 million).
- The most recent figure is from GALECTIN THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: